To assess an association between OCT1 polymorphisms and metformin intolerance among diabetic mellitus (DM) Thai patients Metformin, Gastrointestinal intolerance, Organic cation transporter1 (OCT1), Polymorphisms
Conditions
Interventions
Metformin tolerance meets one of the following criteria:
1. The patient can take metformin at a dose of 2,000 mg/day or more than 2,000 mg/day without experiencing gastrointestinal side effects.
2. A
Health Services Research,Health Services Research
Sponsors
Ratchadapisek Research Funds (type1), faculty of medicine
Eligibility
Sex/Gender
All
Age
30 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of diabetes mellitus 2. Age more than 30 years old 3. History of treatment with metformin (during treatment or ever taking)
Exclusion criteria
Exclusion criteria: 1. The patient who discontinue metformin or decrease the dosage for reasons other than gastrointestinal side effects or contraindications to metformin use such as lactic acidosis, B12 deficiency, renal function, etc. 2. Pregnancy 3. Advanced cancer 4. The patient who diagnosed as irritable bowel syndrome 5. Cirrhosis with Child-Pugh classification B and C 6. The patient declined to participate in the study 7. The patient who diagnosed as AIDS (Acquired Immune Deficiency Syndrome)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OCT1 polymorphism at rs628031 At the end of the study Direct DNA sequencing (Sanger sequencing) | — |
Secondary
| Measure | Time frame |
|---|---|
| OCT1 polymorphism at rs12208357 At the end of the study Direct DNA sequencing (Sanger sequencing),OCT1 polymorphism at rs72552763 At the end of the study Direct DNA sequencing (Sanger sequencing),OCT1 polymorphism at rs1867351 At the end of the study Direct DNA sequencing (Sanger sequencing) | — |
Countries
Thailand
Contacts
Public ContactPiyanuch Piyasatit
Police General Hospital
Outcome results
None listed